Fast track to clinical proof of concept

Tailored solutions for effective collaboration

18.OCT.2017
Katrin Kaarna MD.
Clinical Research Centre
Tartu University/ Tartu University Clinics
EATRIS PURPOSE

EATRIS is a permanent EU biomedical research infrastructure. The purpose is to **accelerate translation of science into medical products** that benefit patients and improve human health.

EATRIS AIMS

1. Improving access to academic expertise
2. Increasing utilisation of academic infrastructure
3. Developing and validating tools that improve pipeline output
4. Facilitating public-private collaboration in research
EATRIS SCOPE

1. Preclinical discovery to clinical proof of concept
2. Product platforms: Advanced Therapy Medicinal Products, Small Molecules, Vaccines
3. Enabling platforms: Biomarkers, Imaging & Tracing

EATRIS BENEFITS

1. Risk-free access to evaluate European expertise
2. Multi-site and multi-disciplinary collaboration in Europe
3. Optimising translation with highly specialized expertise, as needed
OTHER RESEARCH INFRASTRUCTURES: ACCESSIBLE VIA CORBEL INNOVATION

- Biobanks
- Data
- Marine organisms
- Systems biology
- Translational research
- Mouse disease models
- Small molecules
- Clinical trials
- Integrating Biology
- Structural biology
- Biomedical imaging
EXAMPLES OF CURRENT PROJECTS

1. 5-site immune-inflammation imaging hub for UK-based large pharma
2. 3-site 89Zr antibody imaging hub for medium European biopharma
3. Single-site primate 89Zr antibody imaging for international Japanese pharma
4. Collaboration with Kyushu University: best practice, staff exchange in joint research
5. **Pre-clinical toxicology – GLP license (Estonia)**

EXAMPLES OF PROJECTS IN DEVELOPMENT

1. EANM EARL accreditation for 89Zr PET-CT imaging, with 10-14 sites in pilot
2. Exploring concept for trial-ready network in tau imaging
3. Imaging of Progressive Supranuclear Palsy and epilepsy patients with a novel tracer
4. **Biomarkers for osteosarcoma for personalized management (Estonia)**
Current trends Biopharma Development Pipeline

- Public funding
  - Fundamental discovery
  - Early translational F.I.M.

- GAP

- Private funding
  - Moves away from early development

- Phase 1
- Phase 2
- Phase 3
Failing too late in development

Ca 65% fail at phase II

Adapted from Paul et al Nat Nev Drug Disc (2010)
Translational Research Perspective

- From deep, intra-disciplinary exploration to multi-disciplinary, validatory research
- Many factors beyond the scientific concept are needed to success:
  - Creating a **product that is viable**
  - Creating and testing a product that fits to the **development workflow** (stage-gating)
  - Convincing **industry** that the products represents value
  - Convincing the **regulators** that the product is safe and effective
  - Convincing the **government officials** that the product is cost-effective
  - Convincing the **doctors** that the product addresses the medical needs
Clinical Research Centre

Fruitful environment for the doctors, scientists, PhD studies, students

Strong support system to assist doctors, scientists etc.

Proactive quality management and monitoring system to ensure high level quality

International competence centre, international partnerships

Harmonized biobanking network

Leading business partner to other Estonian hospitals, scientific institutions and Estonian government

Different types of trainings and learning courses

Clinical Research is a mutual part of daily work of Medical doctor

Conduct of clinical research according to international standards and providing high level data

Training, usage and outsourcing of study site coordinators

Mapping of biobanks and integrating to international systems

International and country level cooperation